Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tirzepatide in Hepatic Impairment
NCT03940742Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) at 336 hours and Maximum Observed Drug Concentration at 336 hours. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03940742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03940742.